Beijing TIROMU Medical Technology Co., Ltd. has announced the completion of a Pre-A financing round worth tens of millions of RMB, as the company continues to develop robotic solutions for ophthalmic microsurgery.

The round was jointly led by Aibo Hongsheng Equity Investment and Qihang Innovation Investment Fund, with participation from Mingheng Meikang Equity Investment. Fenghe Capital acted as the exclusive financial advisor.

According to publicly available information, the proceeds will primarily be used to advance clinical trials and registration filing for TIROMU’s fundus injection surgical robot, accelerate R&D iteration of its general-purpose ophthalmic surgical robot, and support the industrialization and commercialization of related technologies. The company has not disclosed the exact financing amount, post-money valuation, or detailed allocation of proceeds.

About TIROMU

TIROMU positions itself as a developer of microsurgical robotic systems, with a focus on intelligent surgical solutions for ophthalmic diseases.

The company’s R&D efforts center on key technologies including high-precision mechanical structures, micro-force feedback control, and intraoperative image fusion. Its core team members come from institutions such as Tsinghua University and Waseda University, as well as medical robotics companies including Ariemedi, Remebot, and Meiya Medical, bringing experience in robotic system development and clinical translation.

TIROMU has already developed a fundus injection surgical robot, which has entered the clinical trial stage. The company is also advancing the development of a next-generation system that integrates intraoperative imaging to support surgical path planning and navigation.

Product Pipeline and Technology Focus

Based on company information, TIROMU’s current product and technology pipeline includes:

Fundus injection surgical robot

The system adopts a six-degree-of-freedom robotic architecture and uses a sliding-rail remote center of motion, or RCM, structure. The company states that the system can achieve a procedural accuracy of up to 2 micrometers and has entered clinical trials.

Surgical robot 2.0 platform

The next-generation system is designed to integrate intraoperative OCT imaging, enabling real-time automated surgical path planning and navigation. TIROMU describes this direction as a step toward an ophthalmic surgical robot with “autonomous driving” capabilities.

Starting from ophthalmic microsurgical robotics, TIROMU is also exploring the potential application of its high-precision microsurgical platform in other specialties, including otolaryngology and neurosurgery. These products remain in the R&D stage, and the company has not yet disclosed their specific product formats or commercialization timelines.

May 4, 2026, MedChina